Swiss Pharma Company Announces $23 Billion U.S. Investment Days After Trump Pledged ‘Major Tariff’ on Drug Imports
SUMMARY
Swiss pharma titan Novartis dropped a $23 billion bombshell, unveiling plans to build seven new U.S. facilities and expand three existing ones over five years. The move, announced in a press release, will create 1,000 direct jobs at Novartis and 4,000 more across the U.S. Six manufacturing plants are planned—two for radioligand therapy in Florida and Texas, with four others TBD—plus a biomedical research hub in San Diego. The company’s boosting sites in Indiana, New Jersey, and California, aiming to make all key drugs for U.S. patients stateside. This landed two days after President Trump, on April 8, vowed at an NRCC dinner to slap “major” tariffs on imported drugs, doubling down April 9, saying firms would “leave China” and build here. Novartis CEO Vas Narasimhan said tariffs, while “painful,” aren’t the main driver—Reuters reported April 10. The plan follows Trump’s tariff push, which also sparked $500 billion pledges from Apple and Stargate (OpenAI, Oracle, SoftBank).
